Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: Disclosed in certain embodiments is an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising: (i) a core comprising a first active agent; (ii) a coating comprising a second active agent layered over the core; and (iii) a material that is sensitive to acidic pH layered over the coated core; wherein the dosage form releases at least about 70% of the second active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.

Abstract: The present invention refers to a particulate pharmaceutical or nutraceutical excipient, a process for the preparation of the particulate pharmaceutical or nutraceutical excipient, a pharmaceutical or nutraceutical composition comprising the particulate pharmaceutical or nutraceutical excipient as well as a process for manufacturing a pharmaceutical or nutraceutical composition.

Abstract: The present invention provides a radiation sensitizer or anti-cancer chemotherapy sensitizer that prevents the decomposition of hydrogen peroxide for a longer period of time, and that maintains its effect. The radiation sensitizer or anti-cancer chemotherapy sensitizer according to the present invention is characterized by using hydrogen peroxide together with a hydrogel containing a crosslinked gelatin gel.

Abstract: The present invention relates to a process for semi-permanent straightening and permanent shaping hair, especially human hair, for improved and milder semi-permanent straightening and permanent shaping. It is found out that when commonly used permanent shaping reducing composition is mixed with another composition comprising predominantly carboxylic acids, the permanent shaping effect of the composition is improved, homogeneous shaping of hair fibers is achieved and natural cosmetic properties of hair is maintained and hair may be semi-permanently straightened before such process.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.

Abstract: A tissue adhesive membrane and a preparation method thereof are provided. The tissue adhesive membrane includes a supramolecular polymer and an enhancer; the supramolecular polymer is prepared by copolymerization of lipoic acid and a biocompatible stabilizer; and the enhancer includes at least one selected from the group consisting of a cationic compound, a cationic polymer, and a metal particle. The tissue adhesive membrane of the present invention can achieve rapid adhesion, seal wounds continuously and effectively, and maintain long-lasting mechanical strength. The components of the tissue adhesive membrane come from natural components of animals and plants, have good biocompatibility, and possess the functions of antibacterial and inhibiting inflammation. The tissue adhesive membrane of the present invention is a hydrophobic adhesive membrane where hydrogen bonding and high surface energy can provide strong adhesion energy and no adverse active groups that may cause irritation or discomfort are contained.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: The preparation method of a starch-based double-loaded functional nanoparticle includes: performing restrictive hydrolysis treatment on egg high-density lipoprotein using proteases to obtain the polypeptide; performing self-assembling on a mixed system containing the polypeptide and quercetin under the alkaline condition to form a micelle nanoparticle; performing covalent grafting reaction on a mixed system containing the micelle nanoparticle and anthocyanin under the alkaline condition to form a graft; and electrostatically compounding carboxymethyl dextrin with the graft to obtain the starch-based double-loaded functional nanoparticle. In the preparation method, raw materials derived from natural sources are used, and the self-assembled colloid nanoparticle with good properties can be obtained by adjusting the pH without any organic reagents.

Abstract: Provided herein are methods utilizing microfluidics for the oxygen-controlled generation of microparticles and hydrogels having controlled microparticle sizes and size distributions and products from provided methods. The included methods provide the generation of microparticles by polymerizing an aqueous solution dispersed in a non-aqueous continuous phase in an oxygen-controlled environment. The process allows for control of size of the size of the aqueous droplets and, thus, control of the size of the generated microparticles which may be used in biological applications.

Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Abstract: A gelled composition includes at least 50% by weight of at least one hydrocarbon oil that includes a content by weight of isoparaffins ranging from 90 to 100%, a content by weight of normal paraffins ranging from 0 to 10% and a content of carbon of biological origin greater than or equal to 90% relative to the total weight of the hydrocarbon oil, and at least 1% by weight of at least one gelling agent chosen from among: polymers chosen from homopolymers and copolymers obtained from at least one monomer chosen from among isoprene, butadiene, styrene and (meth)acrylates, and the mixtures of same, and non-polymer gelling agents, relative to the total weight of the gelled composition.

Abstract: The present invention is directed to a biocompatible adhesive system comprising a) a hydrogel comprising a first polymer network and a second polymer network, wherein the first polymer network comprises covalent crosslinks and the second polymer network comprises ionic crosslinks; b) a high density primary amine polymer; and c) a coupling agent. The present invention also provides methods preparing and using the biocompatible adhesive system.

Abstract: The present invention relates to potassium hydrogen alkylhydroxamate compounds and compositions and formulations comprising same, processes for preparing the inventive potassium hydrogen alkylhydroxamate compounds, as well as applications thereof including the use of the inventive compounds and compositions in formulations of products or components of products.

Abstract: Disclosed are nano/micromotor devices, systems, and methods for providing payloads in the gastrointestinal system. In one aspect, a micromotor for a gastrointestinal tract includes a micromotor body including a one or more material layers to provide a structure that surrounds a hollow interior region and has an opening to an exterior of the micromotor body; one or more particles including a biocompatible metal element, the one or more particles contained in the interior region of the micromotor body; a coating coupled to the structure of the micromotor body; and a payload material, in which the micromotor is structured to move in a fluid of a gastrointestinal system based on a reaction between the one or more particles and a constituent or a condition of the fluid, such that the reaction generates bubbles that accelerate out of the opening of the micromotor body to propel the micromotor in the fluid.

Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein.